Delivery Order SPE2DB24D1201-SPE2DB25FJDUK
- Not listed
- The Defense Logistics Agency awarded a $4,076.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 40 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. The contract, awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. No set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $1,831.88 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 20 mg, a prescription stimulant medication commonly used to treat attention-deficit/hyperactivity disorder. The award, issued on July 8, 2025, with an ultimate completion date of July 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. This order was fulfilled from AmerisourceBergen's place of performance in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,328.29 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. The award, issued on August 15, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 18, 2025. This contract was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $1,637.94 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 40 mg, a prescription medication commonly used to treat attention-deficit/hyperactivity disorder. This contract, awarded on September 2, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,963.11 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 40 mg, a prescription medication commonly used to treat attention deficit hyperactivity disorder. This contract, awarded on June 6, 2025, with an ultimate completion date of June 9, 2025, was issued on a firm fixed-price basis without set-aside restrictions, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,634.42 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price delivery order was issued on August 26, 2025, with an ultimate completion date of August 27, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,350.61 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 40 mg, a prescription stimulant medication commonly used to treat attention-deficit/hyperactivity disorder. The contract, established on September 8, 2025, with a completion date of September 9, 2025, was awarded under firm fixed pricing with no set-aside designation, indicating competitive selection. Performance will be executed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $2,239.00 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. The contract was competitively awarded without set-aside designation and is classified as a firm fixed price delivery order, with an ultimate completion date of August 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of...
- The Defense Logistics Agency awarded a delivery order valued at $1,783.60 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 30 mg, a prescription stimulant medication commonly used to treat attention-deficit/hyperactivity disorder. The award, issued on August 25, 2025, with completion expected by August 26, 2025, was structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award based on open competition. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a $2,090.85 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 30 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder (ADHD). This competitively awarded, firm fixed-price delivery order was issued on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a direct fulfillment of pharmaceutical supply needs through the federal medical procurement system. The...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDUKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,002.38 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 40 mg, a prescription medication commonly used to treat attention deficit hyperactivity disorder. Issued on August 5, 2025, with an ultimate completion date of August 6, 2025, this firm fixed-price delivery order represents a single-transaction procurement under a competitive, non-set-aside arrangement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates extensive experience fulfilling DLA medical procurement requirements across multiple therapeutic domains, positioning the company as a critical pharmaceutical vendor for Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 8/5/25 |